3-methoxycyclobutane-1-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-methoxycyclobutane-1-carboxamide
• 英文别名: 3-Methoxycyclobutane-1-carboxamide
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: HRVPOSMAJRIZSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  草酰氯 、 3-methoxycyclobutane-1-carboxamide 以 1,2-二氯乙烷 为溶剂， 生成 3-methoxycyclobutane-1-carbonyl isocyanate
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER
  [FR] COMPOSITIONS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION DE PETITES MOLÉCULES DANS LE TRAITEMENT DU CANCER

  摘要：

  Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one novel compound disclosed herein to a subject having cancer. In some embodiments, methods of treating cancers can include administering a pharmaceutical composition disclosed herein to a subject, the composition including at least one of the novel compounds disclosed herein, and optionally, one additional agent.

  公开号：

  WO2023111996A1
• 作为产物：
  描述：

  反式-3-甲氧基环丁烷羧酸 在 吡啶 、 二碳酸二叔丁酯 、 碳酸氢铵 作用下， 以 四氢呋喃 为溶剂， 以70 %的产率得到3-methoxycyclobutane-1-carboxamide
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER
  [FR] COMPOSITIONS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION DE PETITES MOLÉCULES DANS LE TRAITEMENT DU CANCER

  摘要：

  Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one novel compound disclosed herein to a subject having cancer. In some embodiments, methods of treating cancers can include administering a pharmaceutical composition disclosed herein to a subject, the composition including at least one of the novel compounds disclosed herein, and optionally, one additional agent.

  公开号：

  WO2023111996A1

文献信息

• [EN] 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD)<br/>[FR] DÉRIVÉS DE 7-OU 8-HYDROXY-ISOQUINOLÉINE ET DE 7-OU 8-HYDROXY-QUINOLÉINE EN TANT QUE MODULATEURS D'ALPHA-1-ANTITRYPSINE POUR TRAITER UNE DÉFICIENCE EN ALPHA-1-ANTITRYPSINE (AATD)
  申请人：VERTEX PHARMA

  公开号：WO2021203028A1

  公开（公告）日：2021-10-07

  7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD).

  7-或8-羟基异喹啉和7-或8-羟基喹啉衍生物作为治疗α-1-抗胰蛋白酶缺乏症（AATD）的α-1-抗胰蛋白酶调节剂。
• ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR
  申请人：AbbVie Inc.

  公开号：US20140303176A1

  公开（公告）日：2014-10-09

  The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH 2 , CH 2 CH 2 , CHFCH 2 and CF 2 CH 2 , R 1 is an oxygen containing cyclic radical selected such as C 3 -C 6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C 1 -C 2 -alkoxy, fluorinated C 1 -C 2 -alkoxy, and a carbonyl oxygen, R 2 is selected from the group consisting of hydrogen, OH and fluorine, R 3a is selected from the group consisting of hydrogen and methyl, R 3b is selected from the group consisting of hydrogen and methyl, R 4 is branched C 4 -C 6 alkyl or branched fluorinated C 4 -C 6 alkyl, and R 5 is inter alia C 1 -C 6 alkyl, fluorinated C 1 -C 3 alkyl, C 1 -C 2 -alkoxy-C 1 -C 4 -alkyl, fluorinated C 1 -C 2 -alkoxy-C 1 -C 4 -alkyl, hydroxy-C 1 -C 4 -alkyl, fluorinated hydroxy-C 1 -C 4 -alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C 3 -C 5 cycloalkyl, fluorinated C 3 -C 5 cycloalkyl, etc.

  本发明涉及新颖的酰基氨基环烷化合物，特别是如下式I所述的化合物及其盐和N-氧化物。这些化合物具有有价值的治疗特性，特别适用于治疗对多巴胺D3受体调节有反应的疾病。在式I中，变量具有以下含义：m为1或2，n为1或2，A选自CH2、CH2CH2、CHFCH2和CF2CH2组成的群，R1为含氧环基，选自C3-C6环烷基，其携带一个或两个选自OH、C1-C2-烷氧基、氟化C1-C2-烷氧基和一个羰基氧的含氧基团，R2选自氢、OH和氟，R3a选自氢和甲基，R3b选自氢和甲基，R4为支链C4-C6烷基或支链氟化C4-C6烷基，R5包括C1-C6烷基、氟化C1-C3烷基、C1-C2-烷氧基-C1-C4-烷基、氟化C1-C2-烷氧基-C1-C4-烷基、羟基-C1-C4-烷基、氟化羟基-C1-C4-烷基、氧杂环丙基、氟化氧杂环丙基、氧杂环戊基、氟化氧杂环戊基、C3-C5环烷基、氟化C3-C5环烷基等。
• [EN] OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE<br/>[FR] DÉRIVÉS D'OXAMIDE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION EN MÉDECINE<br/>[ZH] 草酰胺类衍生物、其制备方法及其在医药上的应用
  申请人：SHENZHEN SALUBRIS PHARM CO LTD

  公开号：WO2021110076A1

  公开（公告）日：2021-06-10

  属于化学药物技术领域，涉及草酰胺类衍生物、其制备方法及其在医药上的应用。具体而言，提供式(I)的化合物或其立体异构体、互变异构体、药学上可接受的盐。这些化合物是选择性因子XIa(Factor XIa，简称FXIa)的抑制剂，还涉及包含这些化合物的药物组合物以及使用该化合物治疗血栓栓塞等疾病的药物中的用途。
• TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3041841B1

  公开（公告）日：2019-06-05
• US9388148B2
  申请人：——

  公开号：US9388148B2

  公开（公告）日：2016-07-12